Posted inHIV/AIDS Infectious Diseases
Once-Weekly Oral Islatravir-Lenacapavir: A New Milestone in HIV-1 Treatment Simplification
A phase 3 trial demonstrates that once-weekly oral islatravir-lenacapavir is as effective and safe as daily bictegravir-emtricitabine-tenofovir alafenamide in maintaining HIV-1 viral suppression, offering a promising option to improve adherence.